Utilization, price, and spending trends for antidepressants in the US Medicaid program

Research in Social and Administrative Pharmacy

Volumn 4, Issue 3, 2008, Pages 244-257

  Chen, Yan ^a   Kelton, Christina M L ^a   Jing, Yonghua ^a   Guo, Jeff J ^a,b   Li, Xing ^a   Patel, Nick C ^a,c  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Antidepressants; Drug price; Drug utilization; Expenditure; Market share; Medicaid

Indexed keywords

ANTIDEPRESSANT AGENT; GENERIC DRUG;

ARTICLE; COST CONTROL; DRUG COST; ECONOMICS; FACTUAL DATABASE; FORECASTING; HUMAN; MAJOR DEPRESSION; MEDICAID; METHODOLOGY; STATISTICAL MODEL; UNITED STATES;

ANTIDEPRESSIVE AGENTS; COST SAVINGS; DATABASES, FACTUAL; DEPRESSIVE DISORDER, MAJOR; DRUG COSTS; DRUGS, GENERIC; FORECASTING; HUMANS; MEDICAID; MODELS, ECONOMIC; UNITED STATES;

EID: 51349166121     PISSN: 15517411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sapharm.2007.06.019     Document Type: Article

References (46)

1. Adelmann P.K. Mental and substance use disorders among Medicaid recipients: prevalence estimates from two national surveys. Adm Policy Ment Health 31 (2003) 111-129
2. National Institute of Mental Health (NIMH). Depression. Available at:. http://www.nimh.nih.gov/publicat/nimhdepression.pdf Accessed 30.04.07
3. Barry C.L., and Thomas M.R. Economic grand rounds: improving the quality of depression care in Medicaid. Psychiatr Serv 56 (2005) 1193-1195
4. Buck J.A., Miller K., and Bae J. Mental Health and Substance Abuse Services in Medicaid, 1995. DHHS pub SMA-02-3713 (2002), Center for Mental Health Services, Rockville, MD
5. Thomas M.R., Waxmonsky J.A., Gabow P.A., Flanders-McGinnis G., Socherman R., and Rost K. Prevalence of psychiatric disorders and costs of care among adult enrollees in a Medicaid HMO. Psychiatr Serv 56 (2005) 1394-1401
6. Greenberg P.E., Kessler R.C., Birnbaum H.G., et al. The economic burden of depression in the United States: how did it change between 1990 and 2000?. J Clin Psychiatry 64 (2003) 1465-1475
7. Goodman W.K. Medications for OCD. Available at:. http://psychcentral.com/lib/2006/medications-for-ocd/ Accessed 30.04.07
8. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58 (2000) 19-36
9. Steffens D.C., Krishnan K.R., and Helms M.J. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 6 (1997) 10-18
10. Henry J.A., Alexander C.A., and Sener E.K. Relative mortality from overdose of antidepressants. BMJ 310 (1995) 221-224
11. Henriksson S., Boëthius G., Håkansson J., and Isacsson G. Indications for and outcome of antidepressant medication in a general population: a prescription database and medical record study, in Jämtland county, Sweden, 1995. Acta Psychiatr Scand 108 (2003) 427-432
12. Martenyi F., Brown E.B., Zhang H., Prakash A., and Koke S.C. Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry 63 (2002) 199-206
13. Goodman W.K. Obsessive-compulsive disorder: diagnosis and treatment. J Clin Psychiatry 60 suppl 18 (1999) 27-32
14. McElroy S.L., Casuto L.S., Nelson E.B., et al. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry 157 (2000) 1004-1006
15. Torrens M., Fonseca F., Mateu G., and Farre M. Efficacy of antidepressants in substance use disorders with and without comorbid depression: a systematic review and meta-analysis. Drug Alcohol Depend 78 (2005) 1-22
16. Food and Drug Administration. FDA approves the first drug for seasonal depression. Available at:. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01388.html Accessed 30.04.07
17. Pincus H.A., Tanielian T.L., Marcus S.C., et al. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA 279 (1998) 526-531
18. Huszonek J.J., Dewan M.J., Koss M., Hardoby W.J., and Ispahani A. Antidepressant side effects and physician prescribing patterns. Ann Clin Psychiatry 5 (1993) 7-11
19. University of Cincinnati College of Pharmacy. The Ohio Medicaid Drug Utilization Review Report 1997-2001 [unpublished]. Ohio Department of Jobs and Family Services, Columbus, OH.
20. Banthin J.S., and Miller G.E. Trends in prescription drug expenditures by Medicaid enrollees. Med Care 44 Suppl (2006) 27-35
21. National Pharmaceutical Council, Inc. Pharmaceutical Benefits Under State Medical Assistance Programs, 2004 (2005), National Pharmaceutical Council, Inc., Reston, VA
22. Charatan F. US spending on prescription drugs rose by 19% in 2000. BMJ 322 (2001) 1198
23. National Institute for Health Care Management (NIHCM). Prescription Drug Expenditures in 2000: The Upward Trend Continues (2001), NIHCM, Washington, DC. http://www.nihcm.org Accessed 30.04.07
24. Centers for Medicare & Medicaid services: state drug utilization data. Available at:. http://www.cms.hhs.gov/MedicaidDrugRebateProgram/SDUD/list.asp Accessed 30.04.07
25. Diebold F.X. Elements of Forecasting. 2nd edition (2001), South-Western Publishing, Cincinnati, OH
26. Jing Y., Kelton C.M.L., Guo J.J., et al. Price, utilization, and spending for antipsychotic medications in the Medicaid program. Drug Benefit Trends 19 (2007) 27-41
27. Jing Y., Kelton C.M.L., Guo J.J., Chen Y., Li X., and Wigle P.R. Price and utilization of statins in the Medicaid program. Drug Benefit Trends 18 (2006) 580-592
28. Centers for Medicare & Medicaid Services. Available at:. http://www.cms.hhs.gov/MedicaidDataSourcesGenInfo/04_MdManCrEnrllRep.asp Access-ed 30.04.07
29. Weissman M.M., Livingston B.M., Leaf P.J., Florio L.P., and Holzer C.I. Affective disorders. In: Robins L.N., and Regier D.A. (Eds). Psychiatric Disorders in America: The Epidemiologic Catchment Area Study (1991), The Free Press, New York, NY 53-80
30. Kessler R.C., Nelson C.B., McGonagle K.A., Liu J., Swartz M., and Blazer D.G. Comorbidity of DSM-3-R major depressive disorder in the general population. Br J Psychiatry 168 (1996) 17-30
31. Kessler R.C., Berglund P., Demler O., et al. The epidemiology of major depressive disorder, results from the National Comorbidity Survey Replication (NCS-R). JAMA 289 (2003) 3095-3105
32. Chen H., Reeves J.H., Fincham J.E., et al. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia medical enrollees in 2001. J Clin Psychiatry 67 (2006) 972-982
33. Stone K., Viera A., and Parman C. Off-label applications of SSRIs. Am Fam Physician 68 (2003) 498-504
34. Food and Drug Administration. FDA launches a multi-pronged strategy to strengthen safeguards for children treated with antidepressant medications. Available at: (2004). http://www.fda.gov/bbs/topics/news/2004/NEW01124.html Accessed 30.04.07
35. Mamdani M.M., Parikh S.V., Austin P.C., and Upshur R.E. Use of antidepressants among elderly subjects: trend and contributing factors. Am J Psychiatry 157 (2000) 360-367
36. Bureau of labor statistics, producer price indices commodity series finished consumer foods-WPUSOP3110. Available at:. http://data.bls.gov/cgi-bin/surveymost?wp Accessed 30.04.07
37. Federal Trade Commission. Generic drug entry prior to patent expiration: an FTC study. Available at: (2002). http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf Accessed 30.04.07
38. Russell J. Marketing: are drugmakers' ads making you loopy?. Available at:. http://www.indystar.com/apps/pbcs.dll/article?AID=/20070611/BUSINESS/706110325/1003/BUSINESS Accessed 18.06.07
39. 100 Leading national advertisers special report: profiles supplement. Advertising Age (2006). http://www.adage.com Accessed 30.04.07
40. Special report: 100 leading national advertisers: U.S. marketer profile edition. Advertising Age (2004). http://www.adage.com Accessed 30.04.07
41. Megabrands 2005: top 200 megabrands ranked by total measured U.S. media in 2005. Available at:. http://www.adage.com Accessed 30.04.07
42. Kaiser Commission on Medicaid and the Uninsured. Medicaid Outpatient Prescription Drug Benefits: Findings from a National Survey, 2003 (2003), Kaiser Commission on Medicaid and the Uninsured, Washington, DC
43. Cook A. How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry. Washington, DC: Congressional Budget Office Report. 1998.
44. Dusing M.L., Guo J.J., Kelton C.M.L., and Pasquale M.K. Competition and price discounts for a hospital buyer in the anti-infective pharmaceutical market. J Pharm Finance Econ Policy 14 (2005) 59-85
45. GlaxoSmithKline. Product pipeline. Available at:. http://www.gsk.com/investors/pp_pipeline_standard.htm Accessed 18.06.07
46. Duggan MG. Does Medicaid pay too much for prescription drugs? A case study of atypical anti-psychotics. National Bureau of Economic Research, Working Paper 9626, 2003.